• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Radicava/Edaravone

Background

Edaravone is a drug sold under the names, Radicava or Radicut. Japan, South Korea, Canada, Switzerland, China, Indonesia, Thailand, Malaysia, Brazil and the United States have approved its use to treat people with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND).

Intravenous (IV) edaravone (Radicut) has been used in Japan since 2001 for the acute treatment of neurological symptoms related to ischemic stroke. Based on its proposed mechanism of action, a Japanese clinician suggested edaravone may be effective in treating ALS/MND. This led Mitsubishi Tanabe Pharma America, the owners of Radicut, to examine this possibility in clinical trials.

Approved in:    Commercial Name:  
Argentina Antixan, Edaranovag, Edaracut, Elavone
Australia Radicava® 30mg/20mL concentrated injection ampoule
Brazil  Radicava® 
Canada  Radicava® injection 30 mg/100 mL 
Radicava Oral Suspension (ORS) 
Japan  Radicut® bag 30 mg/100 mL   

Radicut® ampule 30 mg/20 mL 

RADICUT® Oral Suspension 2.1% 
Indonesia   Radicava® IV concentrate solution for infusion 30 mg/20 mL 
Malaysia  Radicava® IV concentrate solution for infusion 30 mg/20 mL 
South Korea  Radicut® ampule 30 mg/20 mL 
Switzerland   Radicava® 30 mg/100 mL 
Radicava® oral suspension 
Thailand   Radicava® 
USA  Radicava® 30 mg/100 mL 
Radicava Oral Suspension (ORS) 

Proposed Mechanism of Action

Several studies have shown that edaravone may act as a free-radical scavenger (or antioxidant) and may protect cells from damage inflicted by oxidative stress, which is hypothesized to be one of the mechanisms causing neuronal toxicity in ALS/MND. Currently it remains unclear how edaravone may have an effect in ALS/MND and studies are ongoing. All other clinical trials using antioxidant compounds have been ineffective for treating ALS/MND to date.

Edaravone IV in Clinical Trials

Multiple clinical trials of edaravone (Radicut) in ALS/MND were conducted in Japan for more than a decade. An initial double-blind, placebo-controlled study (MC-186) demonstrated a trend towards benefit for those treated with edaravone, but this was not statistically significant. Follow up (post-hoc) analysis revealed that a subgroup of participants earlier in the disease appeared to benefit compared to those further progressed. A second double-blind, placebo-controlled clinical trial was conducted, enrolling only individuals with the earlier disease criteria observed to benefit in the previous study and a statistically significant benefit was observed, with a difference of 2.49 ALSFRS-r points between the active treatment and placebo groups over 24 weeks. These results led to approval of edaravone in several countries, notably by the United States FDA in 2017 as Radicava.

Since approval of IV Radicava, MT Pharma has created an oral suspension formulation, which was approved by the FDA as Radicava ORS and Health Canada as Radicava Oral Suspension in 2022. Further clinical trials demonstrated that the oral edaravone acts in an equivalent manner in the body, is safe and is well tolerated.

Another oral formulation of edaravone, TW001, was created by the company Treeway in The Netherlands. TW001, also called FAB122, was tested in a double-blind, placebo-controlled Phase 3 clinical trial across Europe, called the ADORE study, that did not demonstrate benefit versus placebo. It is unknown how comparable this form of edaravone is to the MT Pharma drug and no detailed comparison has been published to date beyond a brief statement in this publication.

Dose and Administration

Administration of edaravone occurs as a 28-day cycle. Edaravone is administered via IV infusion of 60 mg over 60 minutes once daily for 14 days followed by 14-days of a treatment-free period, after which the cycle repeats with a change to edaravone only on 10 out of 14 days during the treatment period. RADICAVA ORS uses the same dosing regimen as RADICAVA IV and is administered orally via mouth or feeding tube with a 5mL syringe.

Reported Side Effects

Edaravone is generally safe and well tolerated at the recommended dose. Commonly reported adverse effects of edaravone IV administration include issues walking, bruising, headaches, fatigue, and constipation. Serious adverse events reported from these studies include respiratory disorders, dysphagia, pneumonia aspiration, and musculoskeletal disorders.

Edaravone should be administered and monitored under the care of a physician.

Current Status

Our understanding of edaravone as a treatment for ALS/MND is constantly evolving. There are conflicting results with some studies suggesting a small benefit while other studies show no benefit. As more information arises, the Alliance will attempt to keep this document updated with current learnings.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: Consult with your doctor to determine if edaravone/Radicava is an option for you. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines currently being used. Your doctor will determine the right plan for your needs.

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Approved Drugs

  • Nuedexta
  • Radicava/Edaravone
  • Riluzole/Tiglutik
  • Rozebalamin / Methylcobalamin
  • Tofersen/Qalsody

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Mike Small, UK

    Mike Small, UK

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Michael Lee, Australia

    Michael Lee, Australia

  • Frank Taylor, USA

    Frank Taylor, USA

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Anita Forte, USA

    Anita Forte, USA

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Animesh Kumar, India

    Animesh Kumar, India

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • John Dinon, Australia

    John Dinon, Australia

  • Timmy, Belgium

    Timmy, Belgium

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Inta Grubb, Australia

    Inta Grubb, Australia

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Jon Newsome, USA

    Jon Newsome, USA

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • John Sweeney, USA

    John Sweeney, USA

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login